Word

IMMUDEX

Status

Registered

Status Code

700

Status Date

Tuesday, January 23, 2024

Serial Number

79333739

Registration Number

7282161

Registration Date

Tuesday, January 23, 2024

Mark Type

5000

Filing Date

Friday, December 10, 2021

Published for Opposition

Tuesday, November 7, 2023

Trademark Owner History

Immudex ApS - Original Registrant

Classifications

5 Preparations for pharmaceutical purposes, namely, pharmaceutical preparations for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; preparations for medical purposes, namely, diagnostic preparations for medical purposes and medical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; chemical-pharmaceutical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T- cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; diagnostic preparations for medical purposes; vaccines; diagnostic preparations for analysis for medical purposes, hereunder for each of the abovementioned preparations for medical analysis of vaccines, immunotherapeutics and cellular therapies, in particular cancer vaccines and immunotherapeutics, borrelia vaccines, TB-vaccines, HIV- vaccines and CMV-vaccines, T-cell therapies, and for use in connection with cancer therapy or other therapy, for medical analysis and treatment of T- cell lymphoma, T-cell infiltration of solid tumors and tissue, and for infectious diseases; diagnostic preparations for analysis for medical purposes, hereunder for use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring

1 Chemicals used in industry and science, in the nature of immune related chemicals for immune cell analysis, immune cell monitoring, immune cell detection and immune cell stimulation and immune related chemicals used in science in the nature of MHC monomer and multimer reagents, MR1 monomer and multimer reagents, CD1 monomer and multimer reagents, antibodies, antigen monomer and multimer reagents, reagents, diagnostic agents, control reagents, oligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; diagnostic reagents for diagnostic being research use, other than medical and veterinary use, and scientific use; research diagnostic reagents for scientific use; diagnostic test materials for scientific and diagnostic, other than medical and veterinary, purposes, namely, diagnostic reagents and preparations, except for medical or veterinary use; diagnostic kits for scientific and diagnostic, other than medical and veterinary, purposes comprised of diagnostic reagents and preparations, except for medical or veterinary use and also comprised of immune related chemicals used in science, in the nature of MHC monomer and multimer reagents, MR1 monomer and multimer reagents, CD1 monomer and multimer reagents, antibodies, antigen monomer and multimer reagents, reagents, diagnostic agents, control reagents, oligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; assays for research purposes; biochemical reagents for non- medical purposes, other than medical and veterinary; chemical and diagnostic preparations for analysis for research purposes related to vaccines and immunotherapy, cancer vaccines, borrelia vaccines, TB- vaccines, HIV-vaccines, CMV-vaccines and other vaccines, and for use in scientific research in connection with therapy and immunotherapy, in particular, for use in cancer therapy, cancer immunotherapy, for analysis of T-cell lymphoma, T-cell infiltration of solid tumors and tissue; chemical, and diagnostic preparations for analysis for research purposes related to analysis of infectious diseases, autoimmunity and for use in scientific research in connection with toxicological studies, transplantation, immune monitoring, and vaccines and T-cell monitoring; chemical reagents for other than medicinal and veterinary purposes

42 Scientific and technological services, namely, scientific research, analysis and testing in the fields of medicine, pharmaceuticals, the immune system, medical diagnostic analysis and vaccines; scientific research; scientific research services, namely, diagnostic services related to research; analysis of medicine, pharmaceuticals and vaccines of others to assure compliance with industry standards; industrial research services in the fields of medicine, pharmaceuticals, the immune system, medical diagnostic analysis and vaccines; basic scientific research and clinical scientific research, hereunder for medicine and vaccine development; product research and development in the field of diagnostic preparations

The mark consists of the stylized wording "IMMUDEX" wherein the letters are colored blue, and the dot of the letter "I" is colored orange.
The color(s) blue and orange is/are claimed as a feature of the mark.

Trademark Events

Jan 23, 2024

Notice Of Registration Confirmation Emailed

Jan 23, 2024

Registered-Principal Register

Nov 7, 2023

Official Gazette Publication Confirmation E-Mailed

Nov 7, 2023

Published For Opposition

Nov 6, 2023

Notification Processed By Ib

Oct 18, 2023

Notification Of Possible Opposition Sent To Ib

Oct 18, 2023

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Oct 18, 2023

Notification Of Notice Of Publication E-Mailed

Oct 5, 2023

Approved For Pub - Principal Register

Oct 4, 2023

Teas/Email Correspondence Entered

Oct 4, 2023

Correspondence Received In Law Office

Oct 4, 2023

Teas Request For Reconsideration Received

Aug 6, 2023

Notification Of Possible Opposition - Processed By Ib

Jul 19, 2023

Notification Of Possible Opposition Sent To Ib

Jul 19, 2023

Notification Of Possible Opposition Created, To Be Sent To Ib

Jul 6, 2023

Notification Of Final Refusal Emailed

Jul 6, 2023

Final Refusal E-Mailed

Jul 6, 2023

Final Refusal Written

Jun 5, 2023

Assigned To Examiner

May 3, 2023

Teas/Email Correspondence Entered

Apr 27, 2023

Correspondence Received In Law Office

Apr 27, 2023

Teas Response To Office Action Received

Apr 2, 2023

New Representative At Ib Received

Nov 14, 2022

Refusal Processed By Ib

Oct 27, 2022

Non-Final Action Mailed - Refusal Sent To Ib

Oct 27, 2022

Refusal Processed By Mpu

Sep 2, 2022

Non-Final Action (Ib Refusal) Prepared For Review

Sep 1, 2022

Non-Final Action Written

Aug 24, 2022

Assigned To Examiner

Feb 26, 2022

Application Filing Receipt Mailed

Feb 22, 2022

New Application Office Supplied Data Entered

Feb 17, 2022

Sn Assigned For Sect 66a Appl From Ib